



The 2025 MPRINT Annual Conference

May 13-15, 2025

Virtual

Tuesday, May 13, 2025

- 9:00 AM Introductions & Overview of Conference Goals
- 9:15 AM Improving outcomes for pregnant women and infants affected by the opioid crisis
- 10:30 AM Therapeutic Perturbation in Early Life Microbial Communities in the Mother-Milk-Infant Triad
- 12:00 PM Break (30 minutes)
- 12:30 PM Predicting and translating fetal drug exposure- Thinking outside the box
- 2:15 PM Break (30 minutes)
- 2:45 PM Real-World and AI-Driven Approaches to Maternal and Child Health
- 3:45 PM Closing Remarks

Wednesday, May 14, 2025

- 9:00 AM Welcome & Day 2 Overview
- 9:10 AM Collaborators & MPRINT: Strengthening Our Network Partnerships
- 10:30 AM Break (15 minutes)
- 10:45 AM Exploring Disability and Chronic Conditions in the MPRINT Mission Discussion
- 11:45 AM Break (45 minutes)
- 12:30 PM Trainee and Fellow Presentations
- 2:15 PM Break (15 minutes)
- 2:30 PM Trainee and Fellow Networking, Engagement & Feedback Breakouts
- 3:30 PM Closing Remarks

Thursday, May 15, 2025

- 9:00 AM Welcome & Day 3 Overview
- 9:05 AM DMKRCC Updates
- 10:15 AM Break (15 minutes)
- 10:30 AM VICE CET Updates
- 11:30 AM UCSD CET Updates
- 12:30 PM Closing Remarks

CME Information

The 2025 MPRINT Annual Conference

Tuesday, May 13, 2025

Day 1

9:00 AM **Introductions & Overview of Conference Goals**
Overview of forum objectives and expectations for the discussion collaborative document

Sara K. Quinney, PharmD, PhD

Professor of Obstetrics and Gynecology and Medicine (Clinical Pharmacology)
Principal Investigator, MPRINT DMKRCC
Indiana University School of Medicine

9:15 AM **Improving outcomes for pregnant women and infants affected by the opioid crisis**

Stephen Patrick, MD, MPH, MS, FAAP

Professor and Chair
Department of Health Policy and Management
Rollins School of Public Health

Sunaya Krishnapura, MD

Vanderbilt School of Medicine, Class of 2025
Pediatrics Resident, Stanford University (upcoming)

10:30 AM **Therapeutic Perturbation in Early Life Microbial Communities in the Mother-Milk-Infant Triad**

Mariana Byndless, D.V.M. PhD

Assistant Professor of Pathology, Microbiology, and Immunology
Vanderbilt University Medical Center

Hui Chu, PhD

Assistant Professor
CIFAR Azrieli Global Scholar
Humans & the Microbiome
University of California, San Diego

Presented by:



12:00 PM **Break (30 minutes)**

All times are listed in U.S. Eastern Time (UTC-4) | 3

Tuesday, May 13, 2025

12:30 PM Predicting and translating fetal drug exposure- Thinking outside the box

12:30 pm, Overcoming current challenges in assessing fetal drug exposure through PBPK modeling

[Jashvant \(Jash\) Unadkat, Ph.D.](#)

Professor

Department of Pharmaceutics

University of Washington

12:55 pm, Current challenges and considerations in translating fetal drug exposure into risk assessment

[Pinky Dua, PhD, Msc](#)

Vice President, Head of Quantitative Clinical Pharmacology

UCB

1:20 pm, Panel Discussion: Predicting and translating fetal drug exposure – Thinking outside the box

Pregnant females take multiple drugs during pregnancy to treat pre-existing conditions or those caused by pregnancy. However, little information is available for most of these drugs as to whether they are safe for the fetus or to inform dosages in pregnancy. In addition, there is some ongoing interest in fetal therapeutics for certain fetal conditions. Predicting fetal drug exposure is a first step towards ascertaining fetal and subsequent neonatal outcomes. While some information on fetal exposure to drugs can be obtained at the time of birth through umbilical venous blood sampling, this information is incomplete. Also, such sampling is infeasible earlier in gestation. Therefore, to fill this gap in knowledge, alternative methods are needed to predict (rather than measure) fetal drug exposure throughout pregnancy. One such method is to utilize quantitative targeted proteomics and PBPK modeling and simulations. In addition, this information needs to be translated into actionable recommendations for patients and practitioners. This session will focus on the status of modeling approaches in predicting fetal drug exposure and how to leverage this modeling and fetal drug exposure data to inform risk in pregnancy and to inform assessments for fetal therapeutics.

Objectives:

1. Understand the current practices in assessing placental transfer.
2. Describe the current status in predicting fetal exposure.
3. Explain current challenges and considerations in translating fetal drug exposure information into risk assessment and informing assessments for fetal therapeutics.

Moderator:

[Elimika Pfuma Fletcher, PharmD, PhD](#)

Policy Lead

Office of Clinical Pharmacology (OCP)

Food and Drug Administration

Tuesday, May 13, 2025

Panel Member(s):

[Jashvant \(Jash\) Unadkat, Ph.D.](#)

Professor

Department of Pharmaceutics

University of Washington

[Pinky Dua, PhD, Msc](#)

Vice President, Head of Quantitative Clinical Pharmacology

UCB

[Anna David, PhD FRCOG](#)

Professor and Consultant in Obstetrics and Maternal Fetal Medicine University College London

[Michelle Pressly, PhD](#)

Staff Fellow

Food and Drug Administration

2:15 PM **Break (30 minutes)**

2:45 PM **Real-World and AI-Driven Approaches to Maternal and Child Health**

2:45 PM, Pharmaco-epidemiology study of Benzonatate using MPRINT-KB and RWD

[Saurabh Rahurkar, DrPH, DDS](#)

Assistant Professor

Department of Biomedical Informatics

The Ohio State University

3:05 PM, Disease Ontology for Pediatric and Maternal populations

[Lei Wang, PhD](#)

Research Scientist

Department of Biomedical Informatics

The Ohio State University

3:20 PM, Q&A

3:45 PM **Closing Remarks**

[Adriana Tremoulet, M.D., M.A.S.](#)

Professor of Pediatrics in the Division of Host-Microbe Systems and Therapeutics in the

Department of Pediatrics

Wednesday, May 14, 2025

Day 2

9:00 AM **Welcome & Day 2 Overview**

Welcome and brief overview of the day's sessions and trainee presentation format

[Prince Kannankeril, MD, MSCI](#)

Richard B. Johnston Jr. MD Endowed Chair in Pediatric Research
Vanderbilt University Medical Center

9:10 AM **Collaborators & MPRINT: Strengthening Our Network Partnerships**

This session will bring together representatives from key research networks and partner organizations to reflect on ongoing collaborations with MPRINT and explore opportunities to strengthen support moving into Year 5. Attendees will discuss how cross-network efforts can be better aligned to maximize collective impact in maternal-fetal and pediatric research.

Discussion Topics:

- Are we effectively supporting network partners in Year 4?
- Where are the gaps or opportunities for greater alignment?
- What more can MPRINT do to strengthen cross-network collaboration?

Moderator:

[Sara K. Quinney, PharmD, PhD](#)

Professor of Obstetrics and Gynecology and Medicine (Clinical Pharmacology)
Principal Investigator, MPRINT DMKRCC
Indiana University School of Medicine

Panel Member(s):

[Sharon Nachman, MD](#)

PI and Chair
IMPAACT Network

[Lauren Aleksunes, PharmD, PhD, DABT](#)

Professor, Pharmacology and Toxicology
Rutgers Ernest Mario School of Pharmacy

[Catriona Waitt, MBChB, PhD](#)

PI, MILK Study
Attaining EQUity of Access TO Reseach (At The EQUATOR)

[Bernard de Bono, MD, PhD](#)

A/Prof (Adjunct) Auckland Bioengineering Institute (University of Auckland, New Zealand)
CEO, Whitby et al LLC, Indianapolis, IN

Collaborators & MPRINT: Strengthening Our Network Partnerships (continued)

Panel Member(s) continued:

[Rachel G. Greenberg, MD, MB, MHS](#)

Chair of the Pediatric Trials Network Steering Committee
Pediatric Trials Network
Associate Professor, Duke Clinical Research Institute

[Daniel Gonzalez, PharmD, PhD](#)

Associate Professor in Medicine
Associate Professor in Pharmacology and Cancer Biology
Member in the Duke Clinical Research Institute
Duke University School of Medicine
Faculty Member, Pediatric Trials Network

[Sonya Tang Girdwood, M.D., Ph.D.](#)

Associate Professor of Pediatrics, Non-Tenure Research Track
Divisions of Hospital Medicine & Translational and Clinical Pharmacology
Co-Program Director, CCHMC Pediatric Clinical Pharmacology T32 Fellowship & K12 Program
Co-Director, Genetic Pharmacology Service
Research Subcommittee Chair, Graduate Medical Education
Hospital Medicine/Clinical Pharmacology Co-Director, Center for Acute Care Nephrology
Cincinnati Children's Hospital Medical Center

[Ogochukwu Amaeze, Ph.D.](#)

Department of Clinical Pharmacy & Biopharmacy
Faculty of Pharmacy
The University of Lagos
Nigeria

[Rebecca Clifton, Ph.D.](#)

Research Professor
Milken Institute School of Public Health
The George Washington University

10:30 AM **Break (15 minutes)**

10:45 AM **Exploring Disability and Chronic Conditions in the MPRINT Mission Discussion**

This session will explore the role of disability and chronic conditions in maternal-fetal and pediatric health. Panelists will discuss key questions about how MPRINT defines and supports research in this area, and how disability fits into the future of the program's mission. Audience participation encouraged.

Moderator:

[Digna R. Velez Edwards, PhD, MS](#)

Division Director, Quantitative Services
Director, Women's Health Research
Professor, Obstetrics and Gynecology
Vanderbilt University Medical Center

Panel Member(s):

[Rupsa C. Boelig, MD MS](#)

Associate Professor
Director, Department of Obstetrics and Gynecology Research Unit
Associate Director, Maternal Fetal Medicine Fellowship
Division of Maternal Fetal Medicine, Department of Obstetrics & Gynecology
Department of Pharmacology, Physiology, and Cancer Biology
Sidney Kimmel Medical College, Thomas Jefferson University

[Tamora Lewis, MD, PhD](#)

Division Head
Clinical Pharmacology & Toxicology
SickKids

[Jonathan Wagner, DO](#)

Professor of Pediatrics
University of Missouri-Kansas City School of Medicine

[Janet Markle, PhD](#)

Assistant Professor of Pathology, Microbiology, and Immunology
Vanderbilt University

[Ellen Wright Clayton, MD, JD](#)

Craig-Weaver Professor of Pediatrics
Professor of Law
Center for Biomedical Ethics and Society
Vanderbilt University

11:45 AM **Break (45 minutes)**

12:30 PM **Trainee and Fellow Presentations**

Human Milk Fatty Acid Profiles Among Breastfeeding Mothers With and Without Systemic Autoimmune Rheumatic Diseases

[Rashmi Dhital, MD](#)

Vanderbilt University Medical Center

Distinct Fecal Microbial and Metabolic Signatures in VEO-IBD

[Kine Kvitne, PhD](#)

Postdoctoral Research

University of California, San Diego

Development and Validation of a Multi-Institutional Electronic Juvenile Idiopathic Arthritis Phenotype

[Anna Patrick, MD, PhD](#)

Assistant Professor of Pediatrics

Division of Rheumatology

Vanderbilt University Medical Center

Mapping pharmaceutical exposures in human milks

[Haoqi Nina Zhao, PhD](#)

University of California, San Diego

Perinatal ampicillin influence on maternal fecal metabolic and microbial profiles

[Simone Zuffa, PhD](#)

Postdoctoral Research

University of California, San Diego

Physiologically-Based Pharmacokinetic Model in Fontan-Associated Liver Disease

[Peirung \(Peggy\) Huang, PharmD, BCMAS](#)

Purdue University

Characterization of Labetalol in Pregnancy: A Clinical Pharmacokinetic Study

[Suhaas Muralidharan, PharmD](#)

Purdue University

State of affairs: physiologically based pharmacokinetic (PBPK) modeling in pregnancy

[Amber N. Rogers](#)

Indiana University School of Medicine

Cardiac Repolarization Status During Pregnancy: Impact of Sex Hormone Changes

[Omar Aboshady, MD, MSc](#)

Purdue University

Trainee and Fellow Presentations (continued)

Effects of Genetic Polymorphisms on OCT1- and OCT2-Mediated Atenolol Uptake

[Mollie M. Walton, MD](#)

Children's Mercy Hospital

Use of physiologically-based pharmacokinetic modeling to inform levetiracetam dosing in children younger than 2 years

[Patty Maglalang, Pharm.D.](#)

UNC, Eshelman School of Pharmacy

2:15 PM **Break (15 minutes)**

2:30 PM **Trainee and Fellow Networking, Engagement & Feedback Breakouts**

Attendees will join small breakout groups to provide feedback to trainee presenters. This session will occur in a Zoom Meeting (not the main webinar).

Please use this Zoom Meeting Link: <https://iu.zoom.us/j/85402440777>

Lead Mentor(s):

[Sharon Nachman, MD](#)

PI and Chair

IMPAACT Network

[Lauren Aleksunes, PharmD, PhD, DABT](#)

PI

NIH Transporter Elucidation Network

[Bernard de Bono, MD, PhD](#)

A/Prof (Adjunct) Auckland Bioengineering Institute (University of Auckland, New Zealand)

CEO, Whitby et al LLC, Indianapolis, IN

[Rachel G. Greenberg, MD, MB, MHS](#)

Chair of the Pediatric Trials Network Steering Committee

Pediatric Trials Network

Associate Professor, Duke Clinical Research Institute

[Sonya Tang Girdwood, M.D., Ph.D.](#)

Associate Professor of Pediatrics, Non-Tenure Research Track

Divisions of Hospital Medicine & Translational and Clinical Pharmacology

Co-Program Director, CCHMC Pediatric Clinical Pharmacology T32 Fellowship & K12 Program

Co-Director, Genetic Pharmacology Service

Research Subcommittee Chair, Graduate Medical Education

Hospital Medicine/Clinical Pharmacology Co-Director, Center for Acute Care Nephrology

Cincinnati Children's Hospital Medical Center

Wednesday, May 14, 2025

3:30 PM **Closing Remarks**

Christina Chambers, PhD, MPH

Professor of Pediatrics at University of California, San Diego & Vice Chair of Clinical Research for the Department of Pediatrics at UCSD and Rady Children's Hospital

Thursday, May 15 ,2025

Day 3

9:00 AM **Welcome & Day 3 Overview**
Brief overview of the day's sessions

[Lang Li, PhD](#)

Professor and Chair
The Ohio State University

9:05 AM **DMKRCC Updates**
This session will highlight recent accomplishments and upcoming initiatives from MPRINT's Data, Modeling, Knowledge, and Research Coordinating Center (DMKRCC). Core leads will share updates on their work and future plans as we move into Year 5.

9:05 AM, Knowledge Base (KB) Core Update

[Lang Li, PhD](#)

Professor and Chair
Department of Biomedical Informatics
The Ohio State University

9:20 AM, Real World Evidence Core (RWE) Update

[Colin Rogerson, MD, MPH](#)

Assistant Professor of Pediatrics
Division of Pediatric Critical Care
Regenstrief Center for Biomedical Informatics
Indiana University School of Medicine

9:35 AM, Pharmacometrics Core Update

[Robert Bies, PharmD, PhD](#)

Professor
Department of Pharmaceutical Sciences
University at Buffalo

9:50 AM, Q&A

[Sara K. Quinney, PharmD, PhD](#)

Professor of Obstetrics and Gynecology and Medicine (Clinical Pharmacology)
Principal Investigator, MPRINT DMKRCC
Indiana University School of Medicine

10:15 AM **Break (15 minutes)**

Thursday, May 15, 2025

10:30 AM VICE CET Updates

[Prince Kannankeril, MD, MSCI](#)

Richard B. Johnston Jr. MD Endowed Chair in Pediatric Research
Vanderbilt University Medical Center

[Digna R. Velez Edwards, PhD, MS](#)

Division Director, Quantitative Services
Director, Women's Health Research
Professor, Obstetrics and Gynecology
Vanderbilt University Medical Center

The Key Role of Biobanks in Delivery of Precision Medicine

[Dan Roden, MD](#)

Professor, Department of Medicine & Pharmacology
Senior Vice President, Personalized Medicine
Professor, Department of Biomedical Informatics
Vanderbilt University

Q&A

[Prince Kannankeril, MD, MSCI](#)

Richard B. Johnston Jr. MD Endowed Chair in Pediatric Research
Vanderbilt University Medical Center

[Wei-Qi Wei](#)

Associate Professor, Department of Biomedical Informatics
Vanderbilt University Medical Center

11:30 AM UCSD CET Updates

[Christina Chambers, PhD, MPH](#)

Professor of Pediatrics at University of California, San Diego & Vice Chair of Clinical Research for the Department of Pediatrics at UCSD and Rady Children's Hospital

[Lars Bode, PhD](#)

Endowed Chair of Collaborative Human Milk Research & Founding Director of the UC San Diego Larsson-Rosenquist Foundation Mother-Milk-Infant Center of Research Excellence (MOMI CORE)

[George Liu, MD, PhD](#)

Chief and Professor,
Pediatric Infectious Diseases
UC San Diego

Thursday, May 15, 2025

UCSD CET Updates (continued)

Shirley Tsunoda, PharmD, FSSP

Professor of Clinical Pharmacy | Associate Dean for Pharmacy Education

Q&A

Adriana Tremoulet, M.D., M.A.S.

Professor of Pediatrics in the Division of Host-Microbe Systems and Therapeutics in the Department of Pediatrics

12:30 PM Closing Remarks

Sara K. Quinney, PharmD, PhD

Professor of Obstetrics and Gynecology and Medicine (Clinical Pharmacology)
Principal Investigator, MPRINT DMKRCC
Indiana University School of Medicine

CME Information

To receive CME credit, you must:

- Have selected CME during registration
- Be logged into the webinar under your full name
- Complete the [CME Evaluation Link](#)

The 2025 MPRINT Annual Virtual Conference May 13-16, 2025 CME Learner Information

Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Indiana University School of Medicine and Indiana Immunization Coalition. Indiana University School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Indiana University School of Medicine designates this activity for a maximum of 15.25 *ANCC contact hours*. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Physicians

Indiana University School of Medicine designates this live activity for a maximum of 11.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Summary

Indiana University School of Medicine (IUSM) policy ensures that those who have influenced the content of a CE activity (e.g. planners, faculty, authors, reviewers and others) disclose all financial relationships with any ineligible companies so that IUSM may identify and mitigate any conflicts of interest prior to the activity. All educational programs sponsored by Indiana University School of Medicine must demonstrate balance, independence, objectivity, and scientific rigor.

The activity evaluation will be sent via email. Within 30-60 days following the activity, learners will receive a separate email with instructions on how to obtain proof of participation in this IUSM activity. For questions and concerns, please contact IU School of Medicine, Division of Continuing Education in Healthcare Professions, 317-274-0104, or cehp@iu.edu



SCHOOL OF MEDICINE
INDIANA UNIVERSITY